Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02785913
Title Lung-MAP: Taselisib as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Southwest Oncology Group

lung squamous cell carcinoma



Age Groups: adult
Covered Countries USA | CAN

No variant requirements are available.